Drug Channels delivers timely analysis and provocative opinions from Adam J. Fein, Ph.D., the country's foremost expert on pharmaceutical economics and the drug distribution system. Drug Channels reaches an engaged, loyal and growing audience of more than 50,000 subscribers and followers. Learn more...
Today’s guest post comes from Logan Melchione, Senior Director of Account Management at Paysign.
Logan describes how some patient affordability vendors capture funds that were intended for patients. She then provides manufacturers with ideas to better manage and oversee copay, bridge, and voucher programs.
In the video below, I discuss how generic drug pricing and the rise of patient-paid, discount card prescriptions pose a risk to pharmacy benefit plans and the PBM business. I also highlight the odd relationship between Prime Therapeutics, Amazon Pharmacy, Express Scripts, and five Blues plans.
The National Association of Specialty Pharmacy (NASP) will host the NASP 2022 Annual Meeting & Expo September 19-22. NASP will celebrate their 10th Anniversary and welcome attendees to a new conference venue – the gorgeous Gaylord Palms Resort & Convention Center, located in Orlando, Florida.
The conference agenda is jam-packed and offers something for everyone, whether you are new to the industry or a seasoned expert.
Conference highlights include:
40+ unique educational sessions organized into four dynamic tracks to help you focus on what is most important to you
Continuing education credits for pharmacists, nurses, and technicians
THREE KEYNOTE PRESENTATIONS
Montel Williams, an Emmy Award winner, decorated former naval officer, inspirational speaker, author, entrepreneur, multiple sclerosis patient and advocate for patients worldwide
Justin Patton, executive coach, will lead the conference in challenging attendees to Reimagine What’s Possible
Monica Pearson, distinguished journalist and humanitarian, and the first woman and first minority to anchor the daily evening news in Atlanta, Georgia
Six pre-conference workshops: Accreditation Workshop (1/2 day), Certified Specialty Pharmacist (CSP) Exam Preparation Course, Home Infusion Workshop (1/2 day), Hospital/Health Systems Specialty Pharmacy Workshop, Specialty Pharmacy Law Conference, and Technology Day Workshop (additional fee required for workshops)
Dynamic Exhibit Hall featuring exhibitors representing all specialty pharmacy industry stakeholders
The ever-popular Women in Specialty Pharmacy Luncheon, featuring motivational keynote speaker Amelia Rose Earhart (additional fee required)
Educate to Cultivate Networking Event -- reconnect with industry colleagues and friends over lunch and learn more about Florida’s oldest industry and time-honored tradition, the authentic and skilled art of cigar rolling (additional fee required)
CE satellite symposia
Poster presentations and author discussions
NASP Industry Awards presentations
The NASP Ron Bookman Scholarship Awards
Direct interaction with industry thought leaders and experts
The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein(paula@drugchannels.net).
Today’s guest post comes from Shawn Seamans, Chief Commercial Officer at CoverMyMeds.
Shawn discusses how technology can be combined with human intervention to better help patients access, afford, and adhere to their therapies. He then describes how three patients benefited from support solutions.
For more information about how CoverMyMeds’ solutions can support the patient journey for your brand, visit their digital commercialization experience.
Last week, the authors of a new JAMA study claimed that “prices for new drugs are skyrocketing.” Their research, along with a simultaneously released New York Times op-ed, received widespread media coverage. Links below.
But as I explain, the study’s headline conclusion is highly misleading. The authors obscure the real story with mathematical sleight-of-hand that misrepresents the underlying data and overlooks the true nature of today’s pharmaceutical innovations.
Most notably, the authors discount the fact that the most expensive new drugs treat ultra-rare conditions affecting extraordinarily small patient populations. Their policy recommendations would therefore have a devastating impact on these patients and their hope for treatments and cures.
As Nobel prize winner Ronald Coase observed: “If you torture the data long enough, it will confess to anything.” Read on and consider what the data are really saying.
Don’t miss the IDN & Bio/Pharma Partnering Summit coming up this summer in Philadelphia, where you'll be part of the important discussions on how to best optimize strategic partnerships to improve patient access and outcomes. This event showcases novel case studies and in-depth sessions that focus on innovative partnership models that will aid in delivering enhanced value, manageable costs and high-quality results.
Visit www.informaconnect.com/IDN for further details and to register. Drug Channels readers will save 10% off when they use code 22DRCH10 and register prior to June 31, 2022.*
The 2022 format includes 2 days of in-person programming, plus a virtual offering of select sessions and recorded presentations available on-demand for 12 months following the conference. Both the in-person and virtual options will include networking opportunities to connect with industry peers and colleagues.
The Summit features coverage on the hottest topics impacting you today, from speakers representing Atrium Health, Bayer, Cone Health, CSL Behring, Fairview Health Services, Nebraska Medicine, NYU Langone Health System, Pfizer, Quil Health, Tempus Labs, TG Therapeutics, University of California, Davis, University of Illinois at Chicago, College of Pharmacy, University of Pennsylvania Health System, Vanderbilt Specialty Pharmacy and Vifor Pharma.
View the agenda to see the complete picture – the program, speakers, and more!
Visit www.informaconnect.com/IDN for further details and to register. Drug Channels readers will save 10% off when they use code 22DRCH10 and register prior to June 31, 2022.*
*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates or other offers. Other restrictions may apply.
The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein(paula@drugchannels.net).
Time for an update to the Drug Channels Institute (DCI) annual analysis of pharmacist salaries and employment.
The retail pharmacy shakeout affected 2021 pharmacist employment. We found that retail pharmacies and drugstores employed fewer pharmacists, while hospitals and outpatient centers continued to add positions. As a result, the share of pharmacists who work in non-retail practice settings reached a new high.
What’s more, average base salaries for retail pharmacists dropped for the second year, while salaries continued to rise for pharmacists employed by hospitals, physician offices, and other non-retail settings. Full salary data below for your enjoyment or sorrow.
As expected, the past few years have been highly challenging for retail-employed pharmacists. Expect further declines as the shakeout continues.
Today’s guest post comes from Bonnie Briggs, Associate Director of Clinical Effectiveness at Wolters Kluwer, Health.
Bonnie describes how pharmaceutical care would benefit from standard medical record identification. She then discusses the practical issues behind implementing and adopting such a system.
A few weeks ago, GoodRx surprised investors with the unpleasant news that a major grocery chain had stopped accepting its discount card for an unspecified number of prescriptions. As I explain below, the unnamed chain appears to be Kroger—the sixth-largest U.S. pharmacy. What’s more, GoodRx disclosed that Kroger accounts for an unexpected one-quarter of its prescription business.
The GoodRx situation highlights crucial issues about the complex web of relationships and conflicts that support today’s discount card model. Below, I break down the economics of the discount card business to help frame the outlook for discount cards.
As I explain, discount cards are really just another form of spread pricing. As the market for patient-paid prescriptions has expanded, disputes about the appropriate split of these spreads will pressure pharmacy-PBM relationships and drive change in the discount card business model.
A well-known African proverb states: “When elephants fight, it's the grass that suffers.” Will investors continue to support GoodRx—or move on to greener pastures? Read on and see what you think.
Today’s guest post comes from Jane Barlow, Chief Clinical Officer, and Susan Raiola, President of Real Endpoints.
Jane and Susan discuss the mechanism and benefits of warranties in the realm of value-based contracts.
To learn more about payer-pharma warranty contracts and whether these agreements can solve issues that limit the utility of more traditional value-based contracts, sign up for Real Endpoints’ free June 9 webinar: Putting Innovative Contracts Under Warranty.
